(-0.14%) 5 461.74 points
(-0.10%) 39 075 points
(0.09%) 17 734 points
(-0.66%) $80.30
(-4.32%) $2.64
(-0.77%) $2 312.90
(0.13%) $28.91
(2.33%) $1 009.40
(0.30%) $0.936
(0.72%) $10.68
(0.47%) $0.792
(-0.14%) $87.37
Live Chart Being Loaded With Signals
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas...
Stats | |
---|---|
Today's Volume | 4 266 |
Average Volume | 0 |
Market Cap | 626.88M |
EPS | $-0.290 ( Q1 | 2024-05-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.510 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0360 (2.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-08 | Scheessele William John | Buy | 276 000 | Stock Options (right to buy) |
2023-12-08 | Prichard Heather Ledbetter | Buy | 290 000 | Stock Options (right to buy) |
2023-12-11 | Prichard Heather Ledbetter | Buy | 525 | Stock Options (right to buy) |
2023-12-08 | Parikh Shamik J | Buy | 283 000 | Stock Options (right to buy) |
2023-12-08 | Cao Yang | Buy | 210 000 | Stock Options (right to buy) |
INSIDER POWER |
---|
-73.68 |
Last 96 transactions |
Buy: 5 191 317 | Sell: 41 628 241 |
Humacyte, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Humacyte, Inc. Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-7.72M (0.00 %) |
EPS: | $-1.070 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-7.72M (0.00 %) |
EPS: | $-1.070 |
FY | 2022 |
Revenue: | $1.57M |
Gross Profit: | $-6.69M (-427.48 %) |
EPS: | $0.620 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.000660 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Humacyte, Inc.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators